Member Info for violindog

Jackdaw, but clearly more sells today than buys..folks still selling into any rise... hence we have lost the small gain from earlier. Surprised we are flat today when Scancell have basically said ( reading between the lines) the SCOPE Trial will meet the ORR.

Oh well... its the end game that counts and we have taken one step further towards it.

Https://www.proactiveinvestors.co.uk/companies/news/1056383/scancell-in-a-strong-position-for-raising-funding-says-panmure-1056383.html

Broker Panmure Liberum has reiterated its buy rating on Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)’s shares with a target price of 23.3p after Scancell announced a strategic partnership with PharmaJet for the supply of the Stratis intramuscular (IM) needle-free injection system.

Scancell will use PharmaJet’s Stratis needle-free intramuscular delivery system for its SCIB1/iSCIB1+ DNA cancer vaccine.

UK

proactive logo

Scancell ‘in a strong position for raising funding’ says Panmure

Published: 12:12 17 Sep 2024 BST

Written by: William Farrington

About this content

View

Scancell Holdings PLC

AIM:SCLP

OTC:SCNLF

Scancell Holdings PLC - Scancell ‘in a strong position for raising funding’ says Panmure

Broker Panmure Liberum has reiterated its buy rating on Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)’s shares with a target price of 23.3p after Scancell announced a strategic partnership with PharmaJet for the supply of the Stratis intramuscular (IM) needle-free injection system.

Scancell will use PharmaJet’s Stratis needle-free intramuscular delivery system for its SCIB1/iSCIB1+ DNA cancer vaccine.

This collaboration is aimed at ensuring a seamless transition into Phase 2/3 clinical trials, anticipated to begin in 2025.

Panmure Liberum remains optimistic about Scancell’s upcoming clinical data, expected in late 2024 and early 2025.

Given the increasing interest in cancer vaccines in recent months we expect the clinical data expected in both Q4-24 and Q1-25 to be both value enhancing and to raise the Scancell profile,” said Panmure.

“We expect this to put the company in a strong position for raising funding for a potentially pivotal clinical trial and/or out-licensing.”

The strategic partnership with Pharmajet is also another tick in the box to help Scancell conclude a deal / sell the platform .

Ruck...yes.. indeed...poorly written when i read my comment back...but I thought the sentiment was clear . As you say the rns is basically telling us all is OK with the SCOPE trial !

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that it has signed a strategic partnership with PharmaJet for supply of the Stratis® Intramuscular (IM) Needle-free Injection System for delivery of Scancell's Immunobody® SCIB1/iSCIB1+ DNA vaccine for both clinical development and commercial use.

Delivering SCIB1/iSCIB1+ intramuscularly via Stratis® has shown effective uptake of the DNA vaccine and has the potential to provide clinical benefit to patients with advanced/metastatic melanoma by allowing native cellular machinery to express the target antigen and induce a potent anti-tumour response. To date, 60 patients across 15 clinical sites have successfully received a total of 171 doses of SCIB1/iSCIB1+ via Stratis®.

Stratis® has U.S. FDA 510(k) marketing clearance, CE Mark, and World Health Organization Prequalification to deliver medications and vaccines either intramuscularly or subcutaneously and has been widely accepted and favoured by patients and clinicians throughout the SCOPE Study.

The license agreement has been completed in preparation for the Phase 2/3 adaptive registrational trial planned for 2025, building on the previously announced exceptional data from the first 13 patients receiving SCIB1 in the ongoing SCOPE trial. Clinical data is expected from SCIB1 and iSCIB1+ in Q4 2024 and Q1 2025, respectively. The delivery of SCIB1/ iSCIB1+ vaccine with Stratis® offers patients speed of treatment as an off the shelf therapeutic cancer vaccine with the convenience of needle-free delivery that enhances the patient experience.

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "Securing long term supply for the PharmaJet Stratis® Intramuscular Needle-free Injection System is an important step in allowing the clinical and commercial development of SCIB1/iSCIB1+. We are pleased that PharmaJet's delivery system works effectively with our SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunisation for patients. Our ultimate goal for Scancell is to deliver an off the shelf, safe, tolerable, effective therapy that can provide potent and durable anti-tumour responses for unresectable stage IV melanoma which currently has a 5-year survival of 35%, according to the SEER database, and we believe this agreement will bring us another step closer to achieving this goal."

Dr Heather Shaw, Consultant Medical Oncologist, Mount Vernon Cancer Centre and the UCLH, commented: "The convenience of an off-the-shelf vaccine for patients, clinicians and the healthcare system is further optimised with the ease of delivery of SCIB1/iSCIB1+ with the Stratis® Needle-free Injection System. Our patients on the SCOPE study are very comfortable with the delivery system and our research team benefit from the convenience of delivering the SCIB1/iSCIB1+ via Stratis®."

Scancell signs strategic partnership with PharmaJet for use of the Stratis® IM Needle-free delivery System in the development of SCIB1/iSCIB1+ cancer vaccine for Advanced Melanoma

They wouldn't do this surely if the trial wasn't going well ??

Well if that RNS tells you the SCOPE Trial is meeting expectations.....brilliant !!

Hi Azzyb,

Folks may need some more info.

Are your Sclp shares held electronically or paper certificates.

Are you a UK National, ie ..able to hold your shares in an ISA ...tax free. If they are in an isa you will need to transfer them to retain the tax free status. Easy done as the new "bank" will do this for you after you have signed up.

You will find that most, if not all banks/ investment companies/trading apps etc etc will charge a small fee.

A great article Burble....

Part of it states

"The trial marks the longest follow-up to date of patients receiving the drugs for advanced melanoma, giving doctors crucial information on how long the treatment is effective for, the overall survival rates and side-effects. While some patients experienced side-effects early on, no new problems arose later. Patients who stopped treatment early because of significant side-effects still benefited from the combination therapy, as the drugs had already taken effect on their immune systems."

Shame the survival stats of the original Scib trial aren't wider known .

C11....or only 34p to my target 😀

WTP...thanks...I agree with your statement. Guess I need to stop checking the SP and BB so often . As you all know I get so frustrated... sorry to drag you all down with me ☹️

.....and not on this miserable AIM market. A post from the other BB (copied below ) says it all...at this rate we will be back to 9p . Can't wait for the SCOPE Trial results.... hopefully back to recent highs and a bid approach to follow!!!

"I have been looking at Summit (SMMT) on Nasdaq.It nearly doubled yesterday on impressive trial results comparing its ivonescimab against Keytruda for lung cancer.It is up 13 fold in a year and yet does not have any approved drugs in the USA. It is unlikely to get quick FDA approval either because the trials were only done in China and that is not usually acceptable to the FDA.Furthermore, the present standard of care for lung cancer is apparently chemo plus Keytruda where the outcome is similar to that for ivonescimab on its own.The simple headlines are impressive, but the truth is that it is probably still years away from making any money in the USA.Even so the market cap for Summit is now $15 billion. Compare that to Scancell's market cap of £157M.It does give a hint of what could happen here though. Xylos"

EE, look at all those sells recently....not hard to accumulate 10 million, last Friday alone could have got you around 1million and there seams a steady supply if required ☹️

Https://vulpesinvest.com/life-sciences/scancell-holdings-plc-multiple-arrows-in-its-quiver/

May be clearer if you download the report . The patents are listed .

Re Patents they were clearly presented in the Vulps report.

PATENTS GRANTED / PENDING – BUTTRESS COMPETITIVE POSITIONING

Despite the company’s modest scale of operations (thus far) it has a fairly wide patent portfolio. The

key patents which have either been granted, or are pending, are detailed in the table below.

Platform Application

Number

Priority

Date

Title Document

Type

Legal

Status

Moditope WO 2022/106696

A3

2020-11-

23

ANTI-TUMOUR RESPONSES TO

CYTOKERATINS

Patent

Application

PENDING

Moditope WO 2020/053304

A2

2018-09-

14

EPITOPES Patent

Application

PENDING

Moditope WO 2017/013425

A1

2015-07-

20

Anti-tumour immune responses to

modified self-epitopes

Granted

Patent

ACTIVE

Moditope WO 2014/023957

A2

2012-08-

07

Anti-tumour response to modified

self-epitopes

Granted

Patent

ACTIVE

ImmunoBo

dy

WO 2008/116937

A2

2007-03-

28

NUCLEIC ACIDS Granted

Patent

ACTIVE

GlyMab

(SC88)

WO 2015/063500

A1

2013-11-

01

Glycans As Functional Cancer Targets

And Antibodies Thereto

Granted

Patent

ACTIVE

GlyMab

(SC2811)

WO 2021/044039

A1

2019-09-

06

SSEA-4 BINDING MEMBERS Patent

Application

PENDING

GlyMab

(SC27)

WO 2021/019095

A1

2019-07-

31

BINDING MEMBERS Patent

Application

PENDING

GlyMab

(SC134)

WO 2021/043810

A1

2019-09-

03

ANTI-FUCOSYL-GM1 ANTIBODIES Patent

Application

PENDING

GlyMab

(SC129)

WO 2017/033020

A1

2015-08-

25

Sialyl-di-Lewis a as expressed on

glycoproteins but not glycolipids as a

functional cancer target and

antibodies thereto

Granted

Patent

ACTIVE

AvidiMab WO 2022/043400

A1

2020-08-

26

NUCLEIC ACIDS ENCODING A

POLYPEPTIDE COMPRISING A

MODIFIED FC REGION OF A HUMAN

IGG1 AND AT LEAST ONE

HETEROLOGOUS ANTIGEN

Patent

Application

PENDING

AvidiMab WO 2021/019094

A1

2019-07-

31

MODIFIED FC-REGIONS TO ENHANCE

FUNCTIONAL AFFINITY OF

ANTIBODIES AND ANTIGEN BINDING

FRAGMENTS THEREOF

Patent

Application

PENDING

Https://www.fiercebiotech.com/biotech/3b-funding-round-bain-set-make-big-biotech-bets

There seams plenty of low hanging fruit around if they fancy some..Scancell fits into their remit... could another US fund follow Redmile🤞

Two 100 sells and a massive spread 9 %..are they deliberately driving the SP down and creating a false market ??

The action today and resulting SP increase, seams more bizarre than Friday...yet on both days the SP has risen. Very encouraging.

Today kicks of the first of 5 Conferences for Scancell ....... shop window prepared and for sale sign up !!

ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit taking place in Boston, Massachusetts, USA from 9-10 September.

Mandeep Sehmi, Head of Business Development, will be attending the conference.

Excellent !! explains the price action on Friday with the late tick up - volume isn't bad today so far either .